Sarepta Therapeutics
Filed with the SEC on · accession 0001193125-26-449721
SRPT filed a 10-Q (quarterly report) with the SEC on Nov 5, 2026. The quarterly report: unaudited results for the quarter plus management’s comments. The stock moved -7.5% by the first close after the filing.
Sarepta Therapeutics filed its quarterly 10-Q report for the period ending September 30, 2026, confirming its status as a large accelerated filer with 107,235,848 shares of common stock outstanding.
Close before
$18.99
Nov 4, 2026
First close after
-7.48%
$17.57
5 trading days
—
Since filing
—
✦ Ask GOAX AI about this filing — what it means for SRPT, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for SRPT?
Click hereSRPT filed a 10-Q (SEC filing). Sarepta Therapeutics filed its quarterly 10-Q report for the period ending September 30, 2026, confirming its status as a large accelerated filer with 107,235,848 shares of common stock outstanding.
The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.
SRPT closed at $18.99 before the filing and $17.57 on Nov 5, 2026 (-7.48%).
Get alerts when SRPT files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days